Share on StockTwits

Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) have been given a consensus rating of “Hold” by the eight analysts that are currently covering the stock, AR Network reports. Four investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $52.57.

In other Integra Lifesciences Holdings Corp news, VP Brian Larkin sold 1,947 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $48.28, for a total transaction of $94,001.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

IART has been the subject of a number of recent research reports. Analysts at Oppenheimer reiterated an “outperform” rating on shares of Integra Lifesciences Holdings Corp in a research note on Wednesday, August 6th. They now have a $57.00 price target on the stock, up previously from $55.00. Analysts at Jefferies Group raised their price target on shares of Integra Lifesciences Holdings Corp from $54.00 to $57.00 in a research note on Wednesday, August 6th.

Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) opened at 48.72 on Friday. Integra Lifesciences Holdings Corp has a one year low of $37.92 and a one year high of $50.25. The stock has a 50-day moving average of $47.5 and a 200-day moving average of $46.41. The company’s market cap is $1.588 billion.

Integra Lifesciences Holdings Corp (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.04. The company had revenue of $231.40 million for the quarter, compared to the consensus estimate of $229.32 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was up 12.6% on a year-over-year basis. On average, analysts predict that Integra Lifesciences Holdings Corp will post $2.94 earnings per share for the current fiscal year.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.

Receive News & Ratings for Integra Lifesciences Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences Holdings Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.